Vasu Divi, MD, Stanford Medicine, Stanford, CA, shares results from a Phase II trial (NCT04710498) of neoadjuvant atezolizumab prior to surgical resection in patients with advanced cutaneous squamous cell carcinoma (cSCC). Atezolizumab was well-tolerated in patients with advanced cSCC and demonstrated a high rate of major and complete pathologic response to the treatment. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть